Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-08-30
1998-05-19
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514211, 540563, 540562, 540543, 540548, 540560, 540564, A61K 3155, C07D49514, C07D49804, C07D49504
Patent
active
057536490
ABSTRACT:
A therapeutic agent for osteoporosis, comprising an azepine compound of the formula ##STR1## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof as an active ingredient, a method for treating osteoporosis comprising administering said compound and a use of said compound for the production of a therapeutic agent for osteoporosis. The compounds of the formula (I) have superior bone resorption-inhibitory activity and act to reduce the increased amount of calcium in blood serum, which is caused by bone resorption. Accordingly, these compounds are usable as pharmaceutical agents to effectively inhibit bone resorption, to prevent decrease of bone mass and to prevent or suppress the increase of calcium amount in blood serum which is caused by the progress of bone resorption, with regard to Paget's disease, hypercalcemia, osteoporosis and so on in which the progress of bone resorption is considered to be deeply associated with the symptom, and to the symptoms of progressing bone resorption (development into osteoporosis) along with inflammatory joint diseases such as rheumatoid arthritis.
REFERENCES:
patent: 3872089 (1975-03-01), Hromatka et al.
patent: 4000289 (1976-12-01), Collins
patent: 4333944 (1982-06-01), Weber et al.
patent: 4959361 (1990-09-01), Walser
patent: 5281590 (1994-01-01), Husa et al.
patent: 5283240 (1994-02-01), Hallinan et al.
patent: 5286858 (1994-02-01), Moriwaki et al.
Moriwaki, M. et al. Chemical Abstracts, 110: 173267 (1989).
Moriwaki, M. et al. Chemical Abstracts, 112: 216937 (1990).
Naka, Y. et al. Chemical Absracts, 111: 214514 (1989).
Moriwaki, M. et al., Chemical Abstracts, 112: 77237 (1990).
Okano, K. et al., Chemical Abstracts, 113: 212028 (1990).
Tahara, T. et al., Chemical Abstracts, 80: 133443 (1974).
Casals-Stenzel, J. et al., Chemical Abstracts, 105: 146244 (1986).
Braquet, P. et al., Chemical Abstracts, 114: 122431 (1991).
Walser, A., Chemical Abstracts, 114: 143456 (1991).
Tahara, T. et al., Chemical Abstracts, 109: 211096 (1988).
Braquet, P. et al., Chemical Abstracts, 116:128977 (1992).
Weber, K. H. et al., Chemical Abstracts, 115: 114558 (1991).
Nakanishi, M. et al., Chemical Abstracts, 78: 84416 (1973).
Nakanishi et al., "Thienodiazepine Derivatives", Chemical Abstracts, vol. 82, No. 9, 1975 Abstract No. 57752u (and JP-A-7411392).
Chiba Kenji
Manabe Shunichi
Moriwaki Minoru
Nakagawa Takashi
Nakamura Takeshi
Japan Tobacco Inc.
Shah Mukund J.
Wong King Lit
Yoshitomi Pharmaceutical Industries Ltd.
LandOfFree
Therapeutic agent for osteoporosis and diazepine compound does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for osteoporosis and diazepine compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for osteoporosis and diazepine compound will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1853191